Matthias Lohle

Summary

Country: Germany

Publications

  1. pmc Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
    Matthias Lohle
    Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
    BMC Neurol 11:112. 2011
  2. doi request reprint Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease
    Alexander Storch
    Division of Neurodegenerative Diseases, Dresden University of Technology, Dresden, Germany
    Neurology 80:1754-61. 2013
  3. doi request reprint Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Martin Wolz
    Department of Neurology, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
    J Neural Transm 117:1279-86. 2010
  4. doi request reprint Non-motor features of Parkinson's disease: depression and dementia
    Heinz Reichmann
    Department of Neurology, Dresden University of Technology, Germany
    Parkinsonism Relat Disord 15:S87-92. 2009
  5. doi request reprint Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease
    Liane Oehme
    Klinik und Poliklinik fur Nuklearmedizin, Universitatsklinikum Carl Gustav Carus, Technische Universitat Dresden, Fetscherstr 74, 01307 Dresden, Germany
    Eur J Nucl Med Mol Imaging 38:1550-9. 2011
  6. doi request reprint Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough
    Matthias Lohle
    Department of Neurology, Dresden University of Technology, Germany
    J Neurol Sci 289:104-14. 2010
  7. doi request reprint Beyond tremor and rigidity: non-motor features of Parkinson's disease
    Matthias Lohle
    Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
    J Neural Transm 116:1483-92. 2009
  8. doi request reprint Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report
    Matthias Lohle
    Department of Neurology, Technical University of Dresden, Dresden, Germany
    Mov Disord 23:1314-6. 2008
  9. ncbi request reprint Orally disintegrating selegiline for the treatment of Parkinson's disease
    Matthias Lohle
    Technische Universitat Dresden, Department of Neurology, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Pharmacother 9:2881-91. 2008
  10. doi request reprint Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors
    Matthias Lohle
    Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany
    Stem Cells 30:570-9. 2012

Collaborators

  • Martin Wolz
  • Karl Strecker
  • Heinz Reichmann
  • Alexander Storch
  • Liane Oehme
  • Bettina Beuthien-Baumann
  • Maria Perick
  • Birgit Herting
  • Jorg van den Hoff
  • Jorg Kotzerke
  • Xina Grahlert
  • Uta Schwanebeck
  • Jens Langner
  • Christine Schneider

Detail Information

Publications11

  1. pmc Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
    Matthias Lohle
    Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
    BMC Neurol 11:112. 2011
    ..Despite numerous drug intervention trials in early PD, there is however still ongoing controversy among neurologists which substance to use for the initial treatment of the disease...
  2. doi request reprint Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease
    Alexander Storch
    Division of Neurodegenerative Diseases, Dresden University of Technology, Dresden, Germany
    Neurology 80:1754-61. 2013
    ....
  3. doi request reprint Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Martin Wolz
    Department of Neurology, Dresden University of Technology, Fetscherstraße 74, 01307 Dresden, Germany
    J Neural Transm 117:1279-86. 2010
    ..LEV was well tolerated in doses up to 2,000 mg/day. Further large controlled studies are warranted to evaluate the impact of LEV on LID in PD patients...
  4. doi request reprint Non-motor features of Parkinson's disease: depression and dementia
    Heinz Reichmann
    Department of Neurology, Dresden University of Technology, Germany
    Parkinsonism Relat Disord 15:S87-92. 2009
    ..These symptoms not only occur during the course of the disease but may even precede the onset of motor symptoms. Typical examples of non-motor features of PD are depression, constipation, REM sleep behaviour disorder, and hyposmia...
  5. doi request reprint Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease
    Liane Oehme
    Klinik und Poliklinik fur Nuklearmedizin, Universitatsklinikum Carl Gustav Carus, Technische Universitat Dresden, Fetscherstr 74, 01307 Dresden, Germany
    Eur J Nucl Med Mol Imaging 38:1550-9. 2011
    ....
  6. doi request reprint Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough
    Matthias Lohle
    Department of Neurology, Dresden University of Technology, Germany
    J Neurol Sci 289:104-14. 2010
    ..Just as the pathogenesis of the disease is manifold, it may be this multilateral approach that eventually leads us to a breakthrough in finding neuroprotective agents for PD, if they exist...
  7. doi request reprint Beyond tremor and rigidity: non-motor features of Parkinson's disease
    Matthias Lohle
    Department of Neurology, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany
    J Neural Transm 116:1483-92. 2009
    ..This article aims to provide an overview of frequently observed non-motor features in PD and discusses prospects and limitations of currently available options for symptomatic treatment of these disturbances...
  8. doi request reprint Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report
    Matthias Lohle
    Department of Neurology, Technical University of Dresden, Dresden, Germany
    Mov Disord 23:1314-6. 2008
    ..i.d., there was pronounced improvement in gait and stance ataxia. Within 24 hours SARA score lowered from 8.5 to 4.5 points. We conclude that 4-AP may be beneficial for interictal cerebellar ataxia in late onset EA2...
  9. ncbi request reprint Orally disintegrating selegiline for the treatment of Parkinson's disease
    Matthias Lohle
    Technische Universitat Dresden, Department of Neurology, Fetscherstrasse 74, 01307 Dresden, Germany
    Expert Opin Pharmacother 9:2881-91. 2008
    ..We conclude that this novel formulation offers an interesting treatment option, especially for patients who report adverse events after initial treatment with conventional selegiline or who suffer from swallowing difficulties...
  10. doi request reprint Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors
    Matthias Lohle
    Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany
    Stem Cells 30:570-9. 2012
    ..We conclude that a reduction of reprogramming factors does not only reduce reprogramming efficiency but may also worsen subsequent differentiation and hinder future application of iPSC in cell replacement therapies...
  11. doi request reprint Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study
    Martin Wolz
    Dept of Neurology, Dresden University of Technology, Fetscherstrasse 74, 01307, Dresden, Germany
    J Neurol 256:488-92. 2009
    ..Although reasons for increased chocolate consumption in PD remain elusive, it may hypothetically be a consequence of the high content of various biogenic amines and/or caffeine analogues with potential antiparkinsonian effects...